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Abstract
Background: Galectin 3 (Gal-3) reflects cardiac fibrosis in heart failure HF, but has also been associated to renal
fibrosis and impaired renal function. Previous research has suggested that Gal-3 could be a cardio-renal biomarker,
but it has never been tested simultaneous in a single study whether Gal-3 reflects echocardiographic measures,
neurohumoral activity and renal function.
The aim of this study was to evaluate the relationship between plasma concentrations of Gal-3 and neurohumoral
activity, myocardial and renal function in patients with HF, including advanced echocardiographic measures and
24-h urinary albumin excretion (albuminuria).
Methods: We prospectively enrolled 132 patients with reduced left ventricular ejection fraction (LVEF) referred to
an outpatient HF clinic. The patients had a median age of 70 years (interquartile rage: 64–75), 26.5 % were female,
median LVEF was 33 % (27–39 %) and 30 % were in NYHA class III-IV.
Results: Patients with plasma concentrations of Gal-3 above the median had significantly lower estimated
glomerular filtration rate (eGFR) and this association remained significant in multivariate regression analysis (β: −0.
010; 95 % CI −0.012–-0.008; P < 0.001), adjusted for age, gender, medical treatment. Plasma concentrations of Gal-3
were not associated with albuminuria (Beta: 0.008; 95 % CI:-0.028–0.045; P = 0.652). There were no association
between plasma concentrations of Gal-3 and myocardial function or structure estimated by LVEF, LVmassIndex,
LVIDd, E/é or LV global longitudinal strain (P > 0.05 for all). In multivariate analyses plasma concentrations of Gal-3
were significantly associated with the cardiac biomarkers: NT-proBNP (β: 0.047; 95 % CI: 0.008–0.086; P = 0.020),
proANP (β: 0.137; 95 % CI: 0.067–0.207;
P < 0.001), chromogranin A (β: 0.123; 95 % CI: 0.052–0.194; P < 0.001) and Copeptin (β: 0.080; 95 % CI: 0.000–0.160;
P = 0.049). Multivariate analysis was adjusted for eGFR, age, gender and medical treatment.
Conclusions: Increased plasma concentrations of Gal-3 are associated with reduced eGFR and increased plasma
concentrations of NT-proBNP, proANP, chromogranin A and Copeptin, but not with echocardiographic parameters
reflecting myocardial function. These results suggest that Gal-3 reflects both increased neurohumoral activity and
reduced eGFR, but not myocardial function in patients with systolic HF.
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Background
Galectin 3 (Gal-3) is a soluble β-galactoside-binding lec-
tin. It is expressed in epithelial and inflammatory cells in
several organs and it is located both intra- and extracel-
lularly [1, 2]. Gal-3 is involved in cellular functions re-
lated to cell adhesion, proliferation and differentiation
[3]. Gal-3 has been linked to fibrosis in a spectrum of
medical conditions including heart failure (HF) [4–7].
Increased plasma concentrations of plasma Gal-3 are
inversely associated to renal function evaluated by esti-
mated glomerular filtration rate (eGFR) in both the gen-
eral population and in HF patients [8, 9]. Increased
plasma concentrations of Gal-3 have predictive value of
deteriorating renal function and de novo renal disease
[10]. It is, however, unknown whether plasma concentra-
tions of Gal-3 are related to 24 h urine albumin excre-
tion (albuminuria), a renal biomarker which also
provides prognostic value in HF [11].
Increased plasma concentrations of Gal-3 are observed in
both acute and chronic HF and it has been associated to in-
creased risk of mortality and re-hospitalization [12–14].
Previous studies have suggested an association between
plasma concentrations of Gal-3 and NT-proBNP [12, 14].
Plasma concentrations of Gal-3 have also been linked to
cardiac fibrosis and it seems reasonable to hypothesize that
it would also be associated to echocardiographic measures
of left ventricular (LV) function [15, 16].
Thus, the clinical potential of Gal-3 and its patho-
physiological aspects are not fully investigated in HF.
We, therefore, wanted to evaluate whether plasma con-
centrations of Gal-3 were associated with I) neurohu-
moral activity (natriuretic peptides), II) myocardial
function estimated by echocardiography and III) renal
function evaluated by eGFR and albuminuria.
Methods
Population
This study was conducted using data from the CardioRen
cohort [17]. Patients were enrolled at their first visit at the
outpatient HF clinic at the North Zealand University Hos-
pital, in the period from January 2011 to November 2012.
Inclusion criteria were LVEF < 45 %, clinical stable (60 days
out of hospital) and stable plasma-creatinine (+/− 10 μM
the last 60 days). A total of 149 patients fulfilled all inclu-
sion criteria and agreed to participate in the study. A total
of 17 patients were excluded from the analyses due to
missing venous blood samples or a missing Gal-3 value.
As a result 132 patients with complete data were included
in this study. All patients provided written informed con-
sent. The study was approved by the Committee on
Health Research Ethics for the Capital Region of Denmark
(H-1-2010-074) and was conducted according to the
Declaration of Helsinki.
Data were collected at the second visit to the HF clinic,
including medical history, present symptoms, functional
class, medication, height, weight, non-invasive blood pres-
sure, heart rate, 12-lead electrocardiogram. Additionally
venous blood samples were taken and patients collected a
24 h urine sample. Advanced echocardiography was
preformed according to standard recommendations of the
European Society of Cardiology [18].
Biomarkers
Hemoglobin and creatinine were analyzed successively
for each patient. Plasma samples for later analysis were
collected in ethylenediamine tetracetic (EDTA) vial, cen-
trifuged at 4 degrees (3,000 rpm in 10 min) and stored
in −80 degrees Celsius.
Plasma concentrations of NT-proBNP, Troponin I and
high sensitive c-reactive protein (hsCRP) were measured
on the Dimension Vista®1500 from Siemens Medical Solu-
tions Diagnostics using the LOCI®-technology (Lumines-
cent Oxygen Channeling Assay) according to the
manufacturer’s instructions [19]. Plasma concentrations of
Copeptin were measured on the Kryptor Compact plat-
form (BRAHMS), assay and validation has been reported
previously [20]. Plasma concentrations of proANP were
measured using an automated immunoluminometric assay
(Thermo-Fisher, Hennigsdorf/Berlin, Germany). Plasma
concentrations of Chromogranin A were measured with an
immuno assay in two steps to quantify the total amount of
Chromogranin A in plasma, as previously described [21].
Gal-3 plasma concentrations were measured with a com-
mercial enzyme-linked immunosorbent assay (BG Medi-
cine, Waltham, MA, USA) [22].
Renal function
Renal function was calculated as eGFR by the Chronic
Kidney Disease Epidemiology Collaboration (CKD-EPI)
equation incorporating age, race, gender, and plasma
creatinine concentration [23]. Impaired renal function
was defined as eGFR <60 mL/min per 1.73 m2. Patients
collected a 24 h urine specimen for albumin excretion
analysis (albuminuria, mg/24 h).
Echocardiography
Echocardiography was performed with the Vivid E9 (Gen-
eral Electric, Vingmed, Horten, Norway) and analyzed off-
line (Echopac BT 12, 1.0, General Electric, Horten, Norway)
by a single trained operator blinded to renal function and
plasma concentrations of Gal-3.
LVEF was calculated by the Simpson biplane model.
LV mass was calculated from the linear dimensions in
the parasternal view and indexed to body surface area
according to gender (LVmassIndex). Maximal left atrial
volume index was determined from the biplane area
method and indexed to body surface area LAESVindex).
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Mitral inflow was determined by pulse wave Doppler re-
cordings and peak velocity of early (E) and atrial filling
(A) and mitral valve deceleration time. Tissue Doppler
velocity was measured at both lateral and septal mitral
annulus for myocardial peak early velocity (e’) and peak
systolic velocity (s’). Mean e’ was calculated from the lat-
eral and septal e’, and used for calculating E/e’. In case of
atrial fibrillation mean value of e’ was calculated from
three consecutive heart cycles. LV global longitudinal
strain (GLS) was assessed by two-dimensional speckle
tracking in the three apical projections (long axis, four
chambers and two chambers). LV GLS was analysed in
17 standardised segments and total LV GLS was calcu-
lated automatically by Echopac software.
Statistics
Baseline clinical and biochemical data were calculated
according to median Gal-3. Dichotomous variables as
proportion in percentages and continuous variables as
median with interquartile range (25–75 %). The two
groups were compared with Pearson Chi square-test for
discrete variables and t-tests (parametric) and Mann
Whitney U-tests (nonparametric) for continuous vari-
ables, as appropriate. Univariate and multivariate linear
regressions analyses were performed for the relation be-
tween plasma concentrations of Gal-3 and each cardio-
vascular biomarker and echocardiographic variable, with
the cardiovascular biomarker or echocardiographic vari-
able as the response variable (+/−median), in separate
models. Explanatory variables (covariates) were chosen
from available established confounders: eGFR, age and
gender. All other potential confounders (diabetes,
NYHA class, LVEF, ischemic heart disease, body mass
index, atrial fibrillation) were eliminated by backward
elimination (P > 0.10) to avoid overfitting of the statis-
tical models. Data quality of covariates included in the
statistical models was > 90 %. Results were considered
statistically significant when P < 0.05 (two-sided).
Results
Baseline characteristic are presented in Table 1. Patients
were divided in two groups with plasma concentrations of
Gal-3 above or below median (median Gal-3: 16.90 ng/mL).
Impaired renal function was present in 28 % of all patients,
defined as eGFR < 60 mL/min/1.73 m2. Ischemic heart
disease verified by previous coronary angiography was
present in 40 %.
Patients with Gal-3 plasma concentrations above the
median were older (P = 0.010), were more symptomatic
(P < 0.001) and more often received a mineralocorticoid
receptor antagonist (P = 0.039) (Additional file 1: Table S1
and Additional file 2). Table 1 also demonstrates that pa-
tients with increased Gal-3 plasma concentrations had
higher plasma creatinine (P = 0.001), lower eGFR (P <
0.001), lower plasma hemoglobin (P = 0.004) and higher
concentrations of NT-proBNP (P < 0.001), hsCRP (P =
0.001), Copeptin (P < 0.001) and Chromogranin A (P =
0.001). These findings suggest that patients with Gal-3
plasma concentrations above median suffer from more ad-
vanced stages of heart failure. In Fig. 1 echocardiographic
variables are presented according to median plasma Gal-3.
Patients with Gal-3 plasma concentrations above the me-
dian had a decreased TAPSE (P = 0.031) and a decreased s’
medial (P = 0.022). Other echocardiographic variables did
not differ significant between the two groups, this included
test for LVmassIndex (P = 0.832) and s’ lateral (P = 0.473).
Table 2 illustrates the associations between both Gal-3
and echocardiographic variables and the associations be-
tween Gal-3 and cardiovascular biomarkers. In univari-
ate analysis both the echocardiographic variables:
TAPSE, E/e’, s’ medial, LAESVindex and the biomarkers:
NT-proBNP, proANP, Chromogranin A, Copeptin, hsCRP
and Troponin I were associated with Gal-3. In multivariate
analysis, adjusted for age, gender, eGFR, treatment with
ACE-inhibitor, Aldosterone Receptor Antagonist, Mineralo-
corticoid receptor antagonist, beta-blocker, NT-proBNP (β:
0.047; 95 % CI: 0.008–0.086; P = 0.020), proANP (β: 0.137;
95 % CI: 0.067–0.207; P < 0.001), Chromogranin A (β:
0.123; 95 % CI: 0.052–0.194; P < 0.001), Copeptin (β: 0.080;
95 % CI 0.000–0.160; P = 0.049) and hsCRP (β: 0.051; 95 %
CI: 0.001–0.101; P = 0.047) were still associated with Gal-3
(Fig. 2). Patients with Gal-3 plasma concentrations above
median had markedly lower eGFR (55 vs. 80 ml/min, P <
0.001). This association remained significant in multivariate
linear regression with Gal-3 as response variable and eGFR
as explanatory variable (β: −0.010; 95 % CI −0.012–-0.008;
P < 0.001), adjusted for age, gender, treatment with ACE-
inhibitor, Aldosterone Receptor Antagonist, Mineralocor-
ticoid receptor antagonist, beta-blocker. There were no sig-
nificant association between Gal-3 and albuminuria (Beat:
0.012; 95 % CI: −0.041–0.065; P = 0.652) (Fig. 3).
Discussion
The main finding of this present study is threefold. First,
plasma concentrations of Gal-3 are associated with neuro-
humoral activity. Second, plasma concentrations of Gal-3
are associated with renal function evaluated by eGFR, but
not with albuminuria. Finally, plasma concentrations of
Gal-3 are not associated with myocardial function evalu-
ated by echocardiography in patients with systolic HF.
Neurohumoral activity and Gal-3
Plasma concentrations of both Gal-3 and NT-proBNP
are elevated in HF patients. In the present study we
observed significant positive associations between Gal-
3 and NT-proBNP and proANP, respectively. These
observations are supported by similar findings in
other studies [12–14]. Previous studies that also
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evaluated the long term prognostic value of Gal-3
have demonstrated that the independent prognostic
value of Gal-3 disappears after adjusting for NT-
proBNP [12, 14, 24–26]. Therefore, although plasma
concentrations of Gal-3 are elevated in HF, most
likely there are no independently associated with in-
creased mortality risk. This present study is the first
to evaluate the relationship of plasma concentrations
of Gal-3 and proANP. The positive association is an-
ticipated and confirms the relationship to natriuretic
peptides. Natriuretic peptides are part of the neuro-
humoral activation in HF and markers of increased
wall stress in the cardiac cambers. Whether plasma
concentrations of Gal-3 are influenced directly by
Table 1 Baseline characteristics according to Galectin 3 plasma concentration above or below median (median = 16.90 ng/mL).
Linear variables presented: median (25–75 % percentiles)
Variable Below median Galectin 3 (n = 64) Above median Galectin 3 (n = 68) P-value
Age, years 68 (62–73) 73 (68–78) 0.010
Female sex, % 21.9 30.9 0.241
BMI, kg/m2 26 (24–29) 27 (23–31) 0.191
NYHA class III-IV, % 15.6 44.1 <0.001
Systolic BP, mmHg 130 (113–143) 122 (110–137) 0.225
Diastolic BP, mmHg 77 (70–84) 73 (68–81) 0.174
Heart rate, beats/min 67 (59–75) 68 (60–78) 0.292
HF duration, months 7.5 (6–12) 12 (6–24) 0.257
Medical history:
Pervious MI, % 46.9 32.4 0.088
Hypertension, % 57.8 64.7 0.405
Atrial fibrillation, % 35.9 32.4 0.664
ICD, % 10.9 13.4 0.663
Diabetes, % 18.8 26.5 0.290
Apoplexia Cerebri/ TCI, % 12.5 22.1 0.148
Medication:
ACE-I, % 64.1 72.1 0.333
ARB, % 31.7 22.1 0.211
Beta-blocker, % 85.9 85.3 0.916
MRA, % 12.5 26.9 0.039
Blood sample analysis:
Hemoglobin, mmol/L 8.9 (8.3–9.4) 8.2 (7.6–8.8) 0.004
Creatinine, umol/L 76.0 (66.0–84.0) 98.0 (81.0–130.5) 0.001
eGFR, mL/min/1.73 m2 81.0 (70.0–88.0) 55.0 (40.5–70.0) <0.001
Galectin 3, ng/mL 13.90 (12.43–14.49) 21.85 (18.65–27.58) <0.001
NTproBNP, pg/mL 920.15 (393.75–1712.30) 1931.15 (736.20–4059.25) <0.001
ProANP, pmol/L 726.89 (470.29–1099.33) 1205 (658.80–1627.44) 0.006
Troponin I, % above median 32,8 38,2 0.519
hsCRP, mg/L 1.64 (0.87–3.30) 3.64 (1.61–8.21) 0.001
Chromogranin A, pmol/L 79.0 (49.0–116.0) 106.5 (72.0–240.0) 0.001
Copeptin, pmol/L 7.89 (5.07–12.62) 10.88 (7.03–32.85) <0.001
Urine Sample analysis:
Albuminuria, mg/24 h 11.0 (9.0–23.5) 14.0 (8.0–29.5) 0.213
Abbreviations: BMI Body mass index, NYHA New York Heart Association, BP Blood pressure, HF Heart failure, MI Myocardial infarction, ICD Implantable cardiac
defibrillator, TCI Transitory cerebral ischemia, ACE-I Angiotensin converting enzyme inhibitor, ARB Aldosterone receptor blocker, MRA Mineralocarticoide receptor
antagonist, eGFR Estimated glomerular filtration rate, NTproBNP N-terminal-pro Brain Natriuretic Peptide, proANP Pro-atrial-natriuretic-peptide, hsCRP high sensitive
C-reactive protein
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Fig. 1 a-f Box plot of medians of echocardiographic variables according to Galectin 3 plasma concentration above median (n = 68) (light blue) or
Galectin 3 plasma concentration below median (n = 64) (dark blue). Patients with plasma concentrations of Galectin 3 above median had a lower
TAPSE and lower s’ medial, other echocardiographic variables did not show signs of an uneven distribution (P > 0.05 for all)
Table 2 Echocardiographic parameters and biomarkers. Linear regression models (response variable: Galectin 3). Multivariate analyses
adjusted for age, gender, eGFR, treatment with beta-blocker, ACE-inhibitor, Aldosterone Receptor Antagonist, Mineralocorticoid receptor
antagonist, beta-blocker
Univariate: Beta (95 %-CI) P-value Multivariate: Beta (95 % CI) P-value
Echocardiographic parameters:
LVIDd -0.036 (-0.124–-0.510) 0.410 -- --
LVmassIndex 0.442×10−3 (-0.912×10−3–1.796×10−3) 0.520 -- --
EF biplane -0.002 (-0.011–0.007) 0.691 -- --
GLS -0.002 (-0.029–0.024) 0.861 -- --
TAPSE -0.195 (-0.353–-0.038) 0.015 -0.073 (-0.211–0.065) 0.298
MV decel time -9.655×10−5 (-0.001–0.001) 0.868 -- --
E/e’ 0.012 (0.000–0.023) 0.049 0.005 (-0.005–0.014) 0.338
s’ medial -0.070 (-0.128–-0.011) 0.020 -0.014 (-0.065–0.036) −0.575
s’ lateral -0.035 (-0.090–0.019) 0.199 -- --
LAESVi 0.009 (0.001–0.017) 0.021 0.004 (-0.003–0.011) 0.222
Biomarkers:
Troponin I 0.175 (0.008–0.341) 0.040 0.055 (-0.089–0.198) 0.451
NTproBNP 0.110 (0.072–0.147) <0.001 0.047 (0.008–0.086) 0.020
proANP 0.320 (0.232–0.407) <0.001 0.137 (0.067–0.207) <0.001
ChromagraninA 0.203 (0.125–0.280) <0.001 0.123 (0.052–0.194) <0.001
Copeptin 0.211 (0.139–0.282) <0.001 0.080 (0.000–0.160) 0.049
hsCRP 0.080 (0.021–0.138) 0.008 0.051 (0.001–0.101) 0.047
Abbreviations: LVIDd Left ventricle internal diameter diastoli, LVmassIndex Left ventricle mass index, EF Ejection Fraction, GLS Global longitudinal strain, TAPSE
Tricuspid annular plane systolic excursion, MV decel time Mitral valve deceleration time, E/e’, s’ Myocardial peak systolic velocity, LAESVi Left atrial end systolic
volume index, NTproBNP N-terminal pro brain natriuretic peptide, proANP Pro atrial natriuretic protein, hsCRP High sensitive C-reactive protein, eGFR Estimated
glomerular filtration rate
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Fig. 2 Scatterplot of the correlation between (a) Galectin 3 plasma concentration and NT-proBNP; (b) Galectin 3 plasma concentration and proANP
and (c) Galectin-3 plasma concentration and Chromogranin A
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increased wall stress or through neurohumoral activa-
tion needs to be examined.
Another cardiac biomarker reflecting neurohumoral
activation is Chromogranin A [21, 27]. No prior study
has evaluated the relationship between plasma concen-
trations of Gal-3 and Chromogranin A. Our findings
suggest a significantly association between plasma con-
centrations of Gal-3 and Chromogranin A, thereby reaf-
firming the relation with the neurohumoral response.
Copeptin, a surrogate marker for vasopressin, involved
in volume regulation and electrolyte homeostasis, is also a
cardiac biomarker reflecting neurohumoral activity.
Copeptin is elevated in HF and predicts mortality risk and
risk of re-hospitalization [28, 29]. In the present study
plasma concentrations Gal-3 are significantly associated to
copeptin. This finding is new and not observed previously.
Another finding of this study is a positive association
between plasma concentrations of Gal-3 and elevated
Fig. 3 Scatterplot of the correlation between (a) Galectin 3 plasma concentration and eGFR and (b) Galectin 3 plasma concentration and albuminuria.
Plasma concentration of Galectin 3 were significantly associated to eGFR in linear univariate (Beta: −0.009; 95%CI: −0.011–-0.007; P < 0.001) and
multivariate analysis (β -0.010; 95%CI: −0.012–-0.008; P < 0.001), adjusted for age and gender, treatment with beta-blocker, ACE-inhibitor, Aldosterone
Receptor Antagonist, Mineralocorticoid receptor antagonist, beta-blocker. Plasma concentration of Galectin 3 were not associated to albuminuria in
linear univariate analyses (Beta: 0.042; 95%CI: −0.018–0.102; P = 0.170)
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plasma concentrations of hsCRP. This finding is in accord-
ance with other studies including HF patients [30, 31]. Gal-3
is also involved in the inflammatory response, and this could
explain a positive association between hsCRP and Gal-3.
Myocardial function and Gal-3
Gal-3 has been linked to cardiac fibrosis in HF, and it would
therefore be reasonable to believe that elevated plasma con-
centrations of Gal-3 would be linked to echocardiographic
findings. In the present study of patients with chronic HF
and reduced LVEF none of the conventional echocardio-
graphic measures were statistically associated to plasma
concentrations of Gal-3. We evaluated both LV systolic
(LVEF, global longitudinal strain, s’) and diastolic parame-
ters (E/e’, e’, E/A, LAESVindex), LVmassIndex, LVIDd and
right ventricle systolic function (TAPSE).
Few prior studies have systematically evaluated the
relationship between echocardiographic measures and
plasma concentrations of Gal-3. The DEAL-HF trial per-
formed serial echocardiographic measures in 240 patients
with HF reduced LVEF and found a positive association be-
tween increased plasma concentrations of Gal-3 and LV re-
modeling estimated by change in LV end diastolic volume
[32]. In a large study of 1440 patients hospitalized with HF
plasma concentrations of Gal-3 did not differ significantly
between patients with reduced LVEF compared to patients
with preserved LVEF after stratifying by New York Heart
Association functional class. However, plasma concentra-
tions of Gal-3 were associated LVEF and LV mass index in
univariate analysis [14]. Shah et al. [33] examined 115 pa-
tients admitted with acute dyspnea, in whom a standard
echocardiography had been performed. It was reported
that plasma concentrations of Gal-3 were associated to sev-
eral echocardiographic parameters reflecting higher LV fill-
ing pressure and valvular disease (mitral inflow ratio, right
ventricular fractional area, right ventricle systolic pressure,
more severe mitral-valve or tricuspid-valve regurgitation)
[33]. On the contrary other studies have found no associ-
ation between plasma concentrations of Gal-3 and myocar-
dial function. In a study of 133 chronic HF patients and 45
decompensated HF patients Tang et al. [9] did not observe
any association between plasma concentrations of Gal-3
and echocardiographic findings neither systolic (LVEF, LV
end systolic diameter, LV end diastolic diameter, LVmas-
sIndex) nor diastolic (mitral inflow ratio, e’, left atrial vol-
ume index). Weir et al. [34] examined 100 patients with
LV dysfunction after acute myocardial infarction and per-
formed cardiac magnetic resonance imaging at baseline
and at 24-week follow-up. Plasma concentrations of Gal-3
were associated to biomarkers reflecting cardiac remodel-
ing, however, there were no association to myocardial func-
tion evaluated by cardiac MRI at baseline or change in
parameters over time. It is uncertain whether plasma con-
centrations of Gal-3 reflect myocardial function, and based
on previous and the present study plasma concentrations
of Gal-3 should likely not play a significantly role in the
evaluation of systolic or diastolic function of the LV in HF.
Renal function and Gal-3
The relationship between plasma concentrations of
Gal-3 and eGFR is well established in both HF patients
and the general population. Gal-3 has been accepted as a
new cardiac biomarker in HF, but also carries potential to
be a renal biomarker due to the close association between
plasma concentrations of Gal-3 and eGFR.
In the present as in previous studies a negative
association between plasma concentrations of Gal-3 and
eGFR in HF patients was observed [9, 14]. Moreover,
Zamora et al. [24] observed that the prognostic value of
plasma concentrations of Gal-3 disappeared after adjust-
ing for renal function. Gopal et al. [35] examined the re-
lationship between plasma concentrations of Gal-3 and
renal function in patients with HF and controls. They
found plasma concentrations of Gal-3 to be correlated
to eGFR in both groups, but Gal-3 were not related to
LVEF or clinical congestion.
No previous studies have examined the relationship
between albuminuria and plasma concentrations of Gal-3
in HF patients. In patients with impaired renal function
O’Seaghdha et al. [10] found no association between albu-
minuria and plasma concentrations of Gal-3. Meijers et al.
[36] have studied the excretion of Gal-3 in both animal
models and in HF and dialysis patients. They observed in-
creased plasma concentrations of Gal-3 in HF patients,
but they did not observe an increased urinary excretion.
They propose that renal clearance of plasma Gal-3 is im-
paired in HF patients, which explains the elevated plasma
concentrations of Gal-3 and the association between renal
function and plasma concentrations of Gal-3 [36]. This
supports the finding in the present study, where no associ-
ation was observed between plasma concentrations of
Gal-3 and albuminuria. Albuminuria and plasma concen-
trations of Gal-3 may, therefore, reflect different pathology
in the kidneys.
Methodological considerations and perspectives
Some methodological limitations of this study should
be addressed. It is a single center study with a limited
sample size. Patients in this study have a short history
of HF, they have been in clinically stable through the
past 3 months and not all patients have been fully
up-titrated in recommended HF treatment. Therefore
the results cannot be extrapolated to other groups of
patients or other stages of heart failure. This study
was conducted as a cross sectional study without
follow-up. Therefore, any firm conclusion concerning
causal relationship between Gal-3 and NT-proBNP
and vice versa has to be interpreted with caution. In
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this study we measured Troponin I, and no subse-
quent analyses for high sensitive troponin were made.
Due to missing follow-up information we were unable
to evaluate the prognostic value of Gal-3.
Plasma concentrations of cardiac biomarkers with renal
excretion must be interpreted with caution in patients
with renal dysfunction, as increased levels could reflect
both decreased clearance and increased cardiac secretion.
While further clinical studies will be necessary to estab-
lish the full benefit of Gal-3 as a cardiac biomarker in HF,
due to its close relationship with eGFR and NT-proBNP,
our studies supports that Gal-3 is elevated in more severe
HF and related to other risk markers. The close relation-
ship with eGFR should be evaluated to create a better un-
derstanding of this relationship. Future studies could
evaluate whether Gal-3 is a cardio-renal marker that e.g.
increases before plasma concentrations of creatinine dur-
ing an acute HF event, a scenario where a new biomarker
is needed. And since no clear association has been found
between Gal-3 and echocardiographic parameters, future
studies should explore the association between plasma
concentrations of Gal-3 and myocardial fibrosis e.g. by late
gate enhancement with magnetic resonance scanning or
by fibrosis identified by myocardial biopsy.
Conclusion
Increased plasma concentrations of Gal-3 are associated
with reduced eGFR and increased neurohumoral activity
(NTproBNP, proANP, Copeptin and Chromogranin A),
but not with echocardiographic parameters of myocar-
dial function in patients with systolic HF.
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